BMY vs DAL
BMY: Bristol Myers Squibb is a leading biopharmaceutical company that leverages a large-scale integrated research platform to deliver innovative medicines across high-impact therapeutic areas like oncology and immunology. DAL: A leading global airline with a focus on premium passenger experiences, diversified revenue streams like MRO and loyalty partnerships, and a unique integrated fuel strategy.
Side-by-side fundamentals
| Metric | BMY | DAL | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $62.48 | $80.15 | |
| Market cap | $127.7B | $52.7B | |
| P/E as of 2026-10-30 | 13.85 | 16.00 | BMY lower |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | n/a | 0.29 | |
| Net margin FY2025, SEC XBRL | +14.6% | +7.9% | BMY higher |
| Operating margin FY2025, SEC XBRL | n/a | +9.2% | |
| ROE FY2025, SEC XBRL | +38.2% | +24.0% | BMY higher |
| ROA FY2025, SEC XBRL | +7.8% | +6.2% | BMY higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-09-30 | 1.86 | 0.54 | DAL lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.2% | +2.8% | DAL higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +7.8% | DAL higher |
| Dividend yield as of 2026-09-03 | 4.03% | 1.10% | BMY higher |
| Dividend streak (yrs) SEC XBRL | 19 | 3 | BMY higher |
| Beta as of 2026-09-03 | 0.23 | 1.73 | |
| 1-year return as of 2026-10-30 close | +37.0% | +40.3% | DAL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.